Skip to content
Menu

Ligand Pharmaceuticals Incorporated LGND

Full chart Compare
Set alert

Price alert · LGND

All alert types
286.85 USD -0.09 (-0.03%)

Regular-session close

286.85 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

283.01 Day range 291.33
181.65 52-week range 322.75
YTD
+51.72%
1 year
+44.12%

Fundamental scorecard

10 of 25 checks passed on LGND’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 0 of 5
  • Growth 5 of 5
  • Profitability 3 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 0 of 5

  • Failed:P/E below its own 5-year median P/E 111 against a 5-year median of 29.9.
  • Failed:P/E under 20 P/E 111: an earnings yield of 0.9%.
  • Failed:Price to sales below its own 5-year median Price to sales 22.6 against a 5-year median of 10.7.
  • Failed:Price to book below its own 5-year median Price to book 6.0 against a 5-year median of 2.4.
  • Failed:Free cash flow yield above 4% Free cash flow of 90.4M is 1.6% of the market value.

Growth 5 of 5

  • Passed:Revenue grew over the last year Revenue of 254M is +1.0% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +10.4% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS 2.30 against 2.03 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years EPS -0.18 in FY 2020, 6.13 in FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +380.1% on the last 12 months.

Profitability 3 of 5

  • Passed:Profitable over the last year Net income of 51.5M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of 5.4%.
  • Passed:Net margin above its 5-year average Net margin of 20.3% against a 5-year average of 18.1%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 90.4M is 175.7% of net income.

Financial health 2 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 608M against short-term liabilities of 501M.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 608M against long-term liabilities of 775M.
  • Failed:Net debt under 40% of equity Net debt of 703M is 73.1% of equity.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of 91.0M is 7.9% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 7.4 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What LGND owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 2.24B of assets

Debt, equity and cash by year

Now: 703M of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

3.32 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

5 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C+2 / 5 overall

  • DCF 3
  • Return on Equity 3
  • Return on Assets 4
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E 29.4×
P/S 13.6×
P/B 3.6×
P/FCF 74.8×
EV/EBITDA 20.4×
EV/Sales 14.7×
FCF Yield 1.3%

Profitability

Gross Margin 97.5%
Operating Margin 17.6%
Net Margin 46.4%
ROE 12.2%
ROIC 2.4%
ROA 8.0%

Growth (YoY)

Revenue 60.4%
Operating Income 308.8%
EPS (diluted) 2886.4%
Free Cash Flow -36.8%

Financial Health

Current Ratio 22.2×
Quick Ratio 22.0×
Debt / Equity 0.4×
Net Debt / EBITDA 1.4×
Interest Coverage 10.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31